A lung-selective delivery of mRNA encoding broadly neutralizing antibody against SARS-CoV-2 infection

[1]  Jincun Zhao,et al.  Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants , 2023, Nature communications.

[2]  D. McManus,et al.  The mRNA Vaccine Technology Era and the Future Control of Parasitic Infections , 2023, Clinical microbiology reviews.

[3]  I. Vizirianakis,et al.  mRNA in the Context of Protein Replacement Therapy , 2023, Pharmaceutics.

[4]  D. Weissman,et al.  A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes , 2022, Science.

[5]  A. Sárközy,et al.  Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[6]  A. Casadevall,et al.  The Potential Role of Passive Antibody-Based Therapies as Treatments for Monkeypox , 2022, mBio.

[7]  Siyan Xu,et al.  Development of mRNA vaccines against respiratory syncytial virus (RSV) , 2022, Cytokine & Growth Factor Reviews.

[8]  Jing-xin Li,et al.  Evidence of the Efficacy and the Effectiveness of First Generation COVID-19 Vaccines in Clinical Trials and Real-world Studies , 2022, Zoonoses.

[9]  D. van Baarle,et al.  A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferrets , 2022, bioRxiv.

[10]  N. Blatt,et al.  Application of Monoclonal Antibody Drugs in Treatment of COVID-19: a Review , 2022, BioNanoScience.

[11]  Fei Shao,et al.  BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection , 2022, Nature.

[12]  Xinquan Wang,et al.  Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages , 2022, bioRxiv.

[13]  Min Wu,et al.  mRNA-based therapeutics: powerful and versatile tools to combat diseases , 2022, Signal Transduction and Targeted Therapy.

[14]  M. Tao,et al.  An efficient approach for SARS-CoV-2 monoclonal antibody production via modified mRNA-LNP immunization , 2022, bioRxiv.

[15]  F. Gao,et al.  An engineered bispecific human monoclonal antibody against SARS-CoV-2 , 2022, Nature Immunology.

[16]  Xia Zhong,et al.  Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters , 2022, Cell Research.

[17]  J. Crowe.  Human Antibodies for Viral Infections. , 2022, Annual review of immunology.

[18]  Huaiyong Chen,et al.  SARS-CoV-2 Infection and Lung Regeneration , 2022, Clinical microbiology reviews.

[19]  Chao-ying Sun,et al.  mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases , 2022, Viruses.

[20]  J. Bloom,et al.  Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry , 2022, Science.

[21]  R. Lu,et al.  Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection , 2022, Journal of biomedical science.

[22]  Qiang Cheng,et al.  On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles , 2021, Proceedings of the National Academy of Sciences.

[23]  S. Thomas,et al.  mRNA Vaccines to Protect Against Diseases. , 2021, Methods in molecular biology.

[24]  J. Mascola,et al.  A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques , 2021, Nature Medicine.

[25]  B. Igyártó,et al.  The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory , 2021, iScience.

[26]  P. Pang,et al.  Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. , 2021, The New England journal of medicine.

[27]  Jennifer Abbasí.  Moderna's mRNA Vaccine for Seasonal Flu Enters Clinical Trials. , 2021, JAMA.

[28]  John D. Davis,et al.  REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19 , 2021, The New England journal of medicine.

[29]  D. Weissman,et al.  mRNA vaccines for infectious diseases: principles, delivery and clinical translation , 2021, Nature Reviews Drug Discovery.

[30]  T. Tharmalingam,et al.  Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases , 2021, Human vaccines & immunotherapeutics.

[31]  R. Andino,et al.  In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains , 2021, Nature.

[32]  P. Taylor,et al.  Neutralizing monoclonal antibodies for treatment of COVID-19 , 2021, Nature Reviews Immunology.

[33]  C. Yao,et al.  SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery , 2021, Cell Reports.

[34]  D. Ho,et al.  Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 , 2021, Nature.

[35]  B. Igyártó,et al.  The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory , 2021, bioRxiv.

[36]  C. Zurla,et al.  Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents , 2021, Nature Biotechnology.

[37]  A. Carfi,et al.  Advancements in mRNA Encoded Antibodies for Passive Immunotherapy , 2021, Vaccines.

[38]  G. Leroux-Roels,et al.  Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial , 2021, Vaccine.

[39]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[40]  Daniel S Spellman,et al.  A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults , 2020, Human vaccines & immunotherapeutics.

[41]  M. Nussenzweig,et al.  SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies , 2020, Nature.

[42]  A. Gintsburg,et al.  Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia , 2020, The Lancet.

[43]  G. Aslanidi,et al.  Intra-tracheal delivery of AAV6 vectors results in sustained transduction in murine lungs without genomic integration , 2020, Gene: X.

[44]  S. Suradhat,et al.  Abrogation of PRRSV infectivity by CRISPR-Cas13b-mediated viral RNA cleavage in mammalian cells , 2020, Scientific Reports.

[45]  J Gomez-Blanco,et al.  DeepEMhancer: a deep learning solution for cryo-EM volume post-processing , 2020, Communications Biology.

[46]  N. Rezaei,et al.  Monoclonal antibody as a potential anti-COVID-19 , 2020, Biomedicine & Pharmacotherapy.

[47]  William J. Liu,et al.  A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 , 2020, Nature.

[48]  Amalio Telenti,et al.  Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody , 2020, Nature.

[49]  Shibo Jiang,et al.  Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2 , 2020, Antiviral Research.

[50]  F. Gao,et al.  A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 , 2020, Science.

[51]  Qiang Cheng,et al.  Selective ORgan Targeting (SORT) nanoparticles for tissue specific mRNA delivery and CRISPR/Cas gene editing , 2020, Nature Nanotechnology.

[52]  Bin Liu,et al.  Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy , 2020, Antibody therapeutics.

[53]  C. Foged,et al.  Opportunities and Challenges in the Delivery of mRNA-Based Vaccines , 2020, Pharmaceutics.

[54]  Daniel G Anderson,et al.  Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[55]  K. Roose,et al.  How mRNA therapeutics are entering the monoclonal antibody field , 2019, Journal of Translational Medicine.

[56]  E. Lindahl,et al.  New tools for automated high-resolution cryo-EM structure determination in RELION-3 , 2018, eLife.

[57]  Örn Almarsson,et al.  A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[58]  Conrad C. Huang,et al.  UCSF ChimeraX: Meeting modern challenges in visualization and analysis , 2018, Protein science : a publication of the Protein Society.

[59]  David Baker,et al.  Foldit Standalone: a video game-derived protein structure manipulation interface using Rosetta , 2017, Bioinform..

[60]  D. Agard,et al.  MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy , 2017, Nature Methods.

[61]  Özlem Türeci,et al.  Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy , 2016, Nature.

[62]  Evelyn Winter,et al.  Development and Evaluation of Lipid Nanoparticles for Drug Delivery: Study of Toxicity In, Vitro and In Vivo. , 2016, Journal of nanoscience and nanotechnology.

[63]  Kai Zhang,et al.  Gctf: Real-time CTF determination and correction , 2015, bioRxiv.

[64]  Vincent B. Chen,et al.  PHENIX: a comprehensive Python-based system for macromolecular structure solution , 2010, Acta crystallographica. Section D, Biological crystallography.

[65]  D. G. Gibson,et al.  Enzymatic assembly of DNA molecules up to several hundred kilobases , 2009, Nature Methods.

[66]  Shubiao Zhang,et al.  Toxicity of cationic lipids and cationic polymers in gene delivery. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[67]  OUP accepted manuscript , 2021, Clinical Infectious Diseases.

[68]  Michel C Nussenzweig,et al.  Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. , 2008, Journal of immunological methods.